BioCentury
ARTICLE | Company News

Evotec, J&J deal

December 24, 2012 8:00 AM UTC

Evotec granted Johnson & Johnson's Janssen Pharmaceuticals Inc. subsidiary exclusive, worldwide rights to develop and commercialize Evotec's portfolio of oral small molecule NMDA receptor NR2B subtype antagonists for depressive disorders. Evotec will receive $2 million up front and is eligible for $6 million in milestones related to confirming preclinical properties of the candidates. Evotec is also eligible for $67 million in clinical, regulatory and launch milestones for a first product, as well as additional reduced milestones for additional indications and/or compounds. Furthermore, the company is also eligible for an additional $100 million in commercial milestones and up to double-digit royalties on resulting products. ...